drugset
Drugs / sacubitril/valsartan
last change Jan 2025 re-read 3 minutes ago

sacubitril/valsartan

also known as Entresto
Developed for
peripheral arterial disease

Trials 0

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Comparator or background therapy1 trial
Phase 2 NCT02636283 Comparator Dec 2017 → Nov 2018 peripheral arterial disease University of Minnesota Terminated No outcome recorded Stop: Enrollment

Press releases naming this drug 26 releases

DateIssuerRelease
2025-01-13 Novartis Pharmaceuticals Novartis Entresto® US patent upheld by US Court of Appeals novartis.com ↗
2023-03-31 Novartis Pharmaceuticals Novartis Entresto receives positive CHMP opinion for pediatric heart failure novartis.com ↗
2021-02-16 Novartis Pharmaceuticals Novartis Entresto® granted expanded indication in chronic heart failure by FDA novartis.com ↗
2021-02-16 Novartis Pharmaceuticals Novartis Entresto® granted expanded indication in chronic heart failure by FDA novartis.com ↗
2020-12-16 Novartis Pharmaceuticals Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF novartis.com ↗
2019-11-17 Novartis Pharmaceuticals Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF novartis.com ↗
2019-09-02 Novartis Pharmaceuticals Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings novartis.com ↗
2019-09-01 Novartis Pharmaceuticals Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint novartis.com ↗
2019-08-19 Novartis Pharmaceuticals Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019 novartis.com ↗
2018-11-11 Novartis Pharmaceuticals New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients novartis.com ↗
2018-08-25 Novartis Pharmaceuticals Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗
2018-05-28 Novartis Pharmaceuticals Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto® novartis.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as sacubitril/valsartan “This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease” NCT02636283 ↗
Known as Entresto “This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain free walking duration on patients with peripheral arterial disease” NCT02636283 ↗
Action Inhibit “by inhibiting the enzyme that degrades it in blood” NCT02636283 ↗
Route Oral “oral route” NCT02636283 ↗